Literature DB >> 15815971

Sedation for the relief of refractory symptoms in the imminently dying: a fine intentional line.

Michael H Levy1, Seth D Cohen.   

Abstract

There is a continuum of the goals of comfort and function in palliative care that begins with comfort and function being equal priorities and sedation being unacceptable. As disease progresses, the goals and preferences of the patient turn to coping with the loss of function caused by the disease and acceptance of unintentional sedation from the disease, its therapies, or symptom relief interventions. As patients approach the end of life, they may need intentional sedation for the relief of refractory symptoms. Such sedation can be divided into three categories: routine, infrequent, and extraordinary with respect to the frequency, difficulty, and risks involved with the drugs and routes of administration required to induce and maintain a level of sedation that relieves the patient's physical and existential symptoms. Extraordinary sedation with continuous infusions of midazolam, thiopental, and propofol can relieve refractory symptoms in most patients in their final days of life. Palliative care clinicians should become comfortable with the ethical justification and technical expertise needed to provide this essential, extraordinary care to the small but deserving number of patients in whom routine and infrequent sedation does not adequately relieve their suffering.

Entities:  

Keywords:  Death and Euthanasia

Mesh:

Substances:

Year:  2005        PMID: 15815971     DOI: 10.1053/j.seminoncol.2005.02.003

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  8 in total

Review 1.  [Sedation in palliative medicine: Guidelines for the use of sedation in palliative care : European Association for Palliative Care (EAPC)].

Authors:  B Alt-Epping; T Sitte; F Nauck; L Radbruch
Journal:  Schmerz       Date:  2010-08       Impact factor: 1.107

2.  Efficacy and safety of deep, continuous palliative sedation at home: a retrospective, single-institution study.

Authors:  Giampiero Porzio; Federica Aielli; Lucilla Verna; Giovanna Micolucci; Paolo Aloisi; Corrado Ficorella
Journal:  Support Care Cancer       Date:  2009-04-03       Impact factor: 3.603

3.  Palliative sedation therapy in a bone marrow transplant unit.

Authors:  Andrea Tendas; Pasquale Niscola; Luca Cupelli; Teresa Dentamaro; Laura Scaramucci; Agostina Siniscalchi; Michela Ales; Marco Giovannini; Alessio Perrotti; Paolo de Fabritiis
Journal:  Support Care Cancer       Date:  2008-11-04       Impact factor: 3.603

Review 4.  [End-of-life dilemmas].

Authors:  Vicente Valentín Maganto; Maite Murillo González
Journal:  Clin Transl Oncol       Date:  2005-08       Impact factor: 3.405

5.  Use of palliative sedation for intractable symptoms in the palliative care unit of a comprehensive cancer center.

Authors:  Ahmed Elsayem; Eardie Curry Iii; Jeanette Boohene; Mark F Munsell; Bianca Calderon; Frank Hung; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2008-05-07       Impact factor: 3.603

6.  Exploring the perceived changes and the reasons why expected outcomes were not obtained in individual levels in a successful regional palliative care intervention trial: an analysis for interpretations.

Authors:  Tatsuya Morita; Kazuki Sato; Mitsunori Miyashita; Miki Akiyama; Masashi Kato; Shohei Kawagoe; Hiroya Kinoshita; Yutaka Shirahige; Sen Yamakawa; Masako Yamada; Kenji Eguchi
Journal:  Support Care Cancer       Date:  2013-08-10       Impact factor: 3.603

7.  Continuous deep sedation and homicide: an unsolved problem in law and professional morality.

Authors:  Govert den Hartogh
Journal:  Med Health Care Philos       Date:  2016-06

8.  Forensic Toxicological and Medico-Legal Evaluation in a Case of Incongruous Drug Administration in Terminal Cancer Patients.

Authors:  Pascale Basilicata; Pasquale Giugliano; Giuseppe Vacchiano; Angela Simonelli; Rossella Guadagni; Angela Silvestre; Maria Pieri
Journal:  Toxics       Date:  2021-12-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.